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Abstract
Lactobacillus acidophilus is homofermentative anaerobic rod-shaped gram-pos-
itive bacteria. L. acidophilous is one of the most common probiotics and is used for 
the treatment of various gastrointestinal, metabolic and inflammatory disorders. L. 
acidophilous produces antimicrobial compounds, maintains gut permeability and 
prevents dysbiosis. L. acidophilus also shows various other properties such as: it is 
anticarcinogenic, lowers serum cholesterol level and improves lactase metabolism 
of host. One of the most significant property of L. acidophilous is that it modulates 
the immune system and can prevent various inflammatory disorders. L. acidophi-
lous influences several immune cells such as Th17 cells and Tregs. Various studies 
reported that inflammation induces bone loss and leads to several bone patholo-
gies such as osteoporosis, rheumatoid arthritis and periodontitis. Recent studies 
have shown the potential of probiotics in preventing inflammation mediated bone 
loss. L. acidophilous is one of these probiotics and is found capable in inhibition of 
various bone disorders. L. acidophilous restores the dysregulated immune homeo-
stasis and prevents inflammatory bone loss. Thus, L. acidophilous can be a potential 
therapeutic for the management of various bone pathologies. In this book chapter 
we reviewed various immunomodulatory properties of L. acidophilous along with 
its efficacy in preventing dysbiosis and maintaining gut permeability. We also 
discussed the potential role of L. acidophilous as a therapeutic for the management 
of inflammation induced bone disorders.
Keywords: probiotics, Lactobacillus acidophilus, immune cells, dysbiosis,  
gut permeability, bone
1. Introduction
The word “Probiotics” is derived from Latin language meaning life [1] and came 
into attention in 1953 by the German scientist Werner Kollath who defined them as 
“active substances that are essential for healthy development of life”. Later on, in 
1992 Fuller defined them as “a live microbial feed supplement which beneficially 
affects the host animal by improving its intestinal microbial balance” [2]. Currently 
probiotics are defined as “live organisms that when administered in adequate 
amounts confer health benefits on the host” and are specified by the Food and 
Agriculture Organization of the United Nations and the World Health Organization 
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(FAO/WHO, 2001). Probiotics are present mainly in fermented foods like cheese, 
bread, wine, kefir and kumis and are commercially available in the market as 
powders, tablets and packets [1]. Probiotics are used from centuries for the treat-
ment of various diseases but it was not known until the 20th century that probiotics 
are healthy bacteria that replace harmful microbes in the gut and regulate gut flora 
[3]. The most extensively used probiotics are Lactobacillus and Bifidobacterium. 
Other common probiotics are Bacillus, Streptococcus, Enterococcus and the fungus 
Saccharomyces [4]. Probiotics are used for the treatment of various gastrointestinal 
disorders like irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), 
infectious diarrhea, Clostridium difficile colitis and antibiotic associated diarrhea 
and many other metabolic disorders such as obesity, diabetes and non-alcoholic 
fatty liver disease [5, 6]. Several mechanisms are involved in preventive activities of 
probiotics such as they modulate the immune system, regulate gut barrier and pro-
tect from pathogens [7]. For a probiotic to be successful it should have various qual-
ities like it should be resistant to the low pH present in gastrointestinal tract, able 
to colonize in the gut, adhere to the epithelium and be able to activate the immune 
system. It should also have several other qualities such as it should be of human ori-
gin, non-pathogenic, noncariogenic and influence the local metabolic activity [4]. 
Lactobacillus acidophilus (LA) is one of the most common probiotics and is present 
in several commercially available food products and dietary supplements [8]. LA 
exhibits antimicrobial, anticarcinogenic and anti-inflammatory properties [8, 9]. 
LA has various properties that make it a good probiotic such as it is acid tolerant, 
bile tolerant, has lactase activity, can adhere to the human epithelial cells, lowers 
serum cholesterol level, prevents infection, modulates immune response, improves 
lactose metabolism of host, etc. [10]. Several commercially accessible strains of LA 
have probiotics ability like LA-1 to LA-5 (Chr. Hansen, Demark), NCFM (Dansico, 
Madison), SBT-2026 (Snow brand milk products, Japan), DDS-1 (Nebraska cul-
tures, Nebraska), etc. LA NCFM is the most common LA strain and is regarded safe 
by the US Food and Drug Administration (FDA) [10]. LA has immunomodulatory 
properties and is considered for the treatment of various inflammatory diseases 
such as IBD, cancer, etc. [11, 12]. Use of probiotics for the prevention of bone loss 
has recently gain much attention. Probiotics prevent osteoporosis and other bone 
diseases like arthritis and periodontitis by influencing the immune system or via 
other mechanisms. Various studies have shown the potential of LA in preventing 
bone diseases [9]. Bone disorders like osteoporosis, rheumatoid arthritis (RA) 
and periodontitis are immune disorders and it is observed that LA has potential of 
preventing these disorders by modulating the immune system. Thus, LA can act as a 
therapeutic for the treatment of various bone fragilities.
In this chapter we summarized some of the mechanisms which are responsible 
for the health promoting effects of LA focussing primarily on immunomodulatory 
properties of LA. We also discussed the role of LA in preventing inflammatory bone 
loss and how modulation of gut microbiota and maintenance of gut integrity by LA 
can play a role in regulating bone health.
2. Lactobacillus acidophilus
LA is a type of lactic acid bacteria (LAB). LAB constitute a group of gram-
positive, acid tolerant, catalase negative, non-sporulating and generally rod-shaped 
bacteria [13] that are frequently associated with dairy, meat and plants [14]. LAB 
produce lactic acid from carbohydrate fermentation which make them important 
in fermentation and agriculture-based industries. They are used for imparting 
unique textures and flavors and for preservation and acidification of different food 
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items [10]. LAB comprised a number of genera such as Lactobacillus, Enterococcus, 
Streptococcus, Cornobacterium, Leuconostoc, Lactococcus, Bifidobacterium and 
Sporolactobacillus which are further subdivided into species, subspecies, variants 
and strains [15, 16]. Lactobacillus is the largest genus of lactic acid bacteria having 
more than 145 species [17]. Lactobacilli is part of human microbial flora which 
colonizes in the human gastrointestinal and urinary tract [18]. Lactobacillus spe-
cies are the first ones to colonize the gut after birth where they provide various 
health promoting effects. Lactobacillus species have various qualities that make 
them suitable as probiotics. They are resistant to stomach pH and bile juices, can 
adhere to the mucosa, inhibit growth of other harmful bacterial species and have 
immunomodulatory properties [19]. Lactobacilli encompass a wide range of species 
that have role in various biochemical and physiological functions [10]. LA is one of 
the most known species belonging to Lactobacillus genus. LA was earlier named as 
Bacillus acidophilus and first isolated in 1900 from the human infant feces by Moro 
[19]. Almost 80% of the yogurts in America have LA [19]. LA is rod shaped homo-
fermentative anaerobic having size of approximatively 2–10 μM. LA is a thermo-
phile and grows optimally at a temperature of 37 to 450 C and at pH range of 4–5 
[16]. Highest growth is observed at pH between 5.5 and 6.0 whereas growth ceases 
at pH 4. Diet is one of the major source of LA in gut. Various commercially available 
food products such as yogurt and milk are supplemented with LA due to its probi-
otic value [19]. LA is part of human microbiota and is isolated from digestive, oral 
and vaginal areas but Claesson’s characterization revealed that gastrointestinal tract 
is its main environment [19]. It is observed that LA supplementation to humans in 
heat killed form is completely safe. It is observed that heat killed LA provides pro-
tection to immunodeficient mice infected with Candida albicans [20]. Simakachorn 
et al. also reported that LA supplementation induces no adverse effect in children 
having diarrhea [21]. LA is found effective in the treatment of various inflamma-
tory disorders like IBD, diabetes, cancer, etc. [19]. LA prevents these inflammatory 
disorders by regulating the immune homeostasis. Therefore, the immunomodula-
tory potential of LA can be used for the management of various disorders. From 
recent studies it is observed that LA also inhibits inflammatory bone loss and can 
prevent various bone fragilities such as osteoporosis, RA and periodontitis. Below 
we reviewed the various immune modifying properties of LA. Later in the chapter, 
we discussed the role of immune modification by LA in prevention of inflammation 
induced bone loss. Apart from immunomodulation LA also prevents dysbiosis and 
increase in gut permeability which are discussed later in the chapter.
2.1 LA role in modulating the immune system
LA has great immunomodulatory properties. Because of the immune modify-
ing properties of LA it is considered for the treatment of various inflammatory 
diseases. LA can be an inexpensive therapeutic for treatment of numerous clinical 
manifestations involving malfunctioning of the immune system. Here we discuss 
various studies highlighting the importance of LA as a potential therapeutic for 
the prevention of several immune related disorders. It is observed that LA and L. 
plantarum supplementation for 60 days enhanced the expression of genes related 
to innate immune response in crayfish [22]. Feeding of probiotic “dahi” consisting 
of LA and Bifidobacterium bifidum reversed decrease in immune response in aging 
mice [23]. LA and Bifidobacterium animalis subspecies lactis decreased inflamma-
tion of intestinal epithelial cells by modifying the toll like receptor 2 (TLR2) medi-
ated Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
mitogen-activated protein kinase (MAPK) signaling pathways [24]. Feeding of milk 
fermented with LA and L. casei increased both the phagocytic and lymphocytic 
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activity in swiss mice [25]. LA strain NCFM increased gram-positive immune 
response in C. elegans by modulating key immune signaling pathways such as p38 
MAPK and β-catenin signaling pathways [26]. LA can be used for the prevention 
of obesity related effects. LA-KCTC3925 supplementation significantly attenuated 
the levels of splenic and hepatic cyclooxygenase-2 (COX-2) mRNA expression and 
intracellular adhesion molecule-1 (ICAM-1) expression in high fat diet induced 
obese mice [27]. LA supplementation generated non-specific immune response in 
germ free mice [28].
LA regulates the secretion of cytokines from various immune cells and main-
tains the balance between inflammatory and anti-inflammatory cytokines. It is 
observed that LA treatment significantly altered the production of interleukin 
(IL)-4 and interferon (IFN)-γ from splenocytes in the presence of purified tumor 
antigen. LA and L. reuteri modulated the cytokine response in neonatal gnotobiotic 
pigs infected with human rotavirus (HRV). LA and L. reuteri treatment in HRV 
infected pigs significantly enhanced the production of Th1 and Th2 cytokine 
responses as indicated by the higher concentration of IL-12, IL-10, IL-4 and INF-γ 
in these pigs. Treated pigs also had higher concentration of transforming growth 
factor (TGF)-β as compared to the controls. Thus, LA and L. reuteri supplemen-
tation can maintain immune homeostasis by regulating TGF-β level after HRV 
infection [29]. LA induced the production of cytokines such as IL-1β, TNF-α, IL-10 
and IFN-γ from human peripheral blood mononuclear cells (PBMCs) [30]. LA 
significantly downregulated the production of anti-inflammatory cytokines and 
reactive oxygen species (ROS) whereas increased the production of anti-inflamma-
tory cytokines from PBMCs isolated from Parkinson’s disease patients [31]. Chen 
et al. showed that LA suppressed IL-17 production in experimental colitis model 
by suppressing expression of IL-23 and TGF-β1 and downstream phosphorylation 
of phospho-signal transducer and activator of transcription 3 (p-STAT3) [11]. It is 
observed that LA downregulated the expression of IL-1α, IL-1β, IL-8, monocyte 
chemoattract protein (MCP)-1 and C-X-C motif ligand 3 (CXCL3) in bovine 
mammary epithelial (BME) cells after Lipopolysaccharide (LPS) challenge. LA 
also increased the expression level of negative regulators of TLRs viz. toll interact-
ing protein, ubiquitin-editing enzyme A20 and single immunoglobulin IL-1 single 
receptor in BME cells after LPS challenge [32]. Thus, LA can be a treatment option 
for bovine mastitis which is characterized by inflammation of the mammary 
glands. LA treatment significantly enhanced the expression of IL-1β, IFN-α, IFN-γ, 
interferon regulatory factor (IRF)-7, interferon-inducible transmembrane protein 
M3 and 2′,5′-oligoadenylate synthetase in chicken macrophages in response to 
avian influenza virus [33]. LA induced the production of TGF-β and inflammatory 
cytokines such as IL-6 and tumour necrosis factor (TNF-α) in dendritic cells (DCs) 
cocultured with intestinal epithelial cells [34]. It is observed that administration of 
LA strain L36 to germ-free mice induced higher expression of cytokines associated 
with Th2 cells such as IL-6, IL-5 and TGF-β and Th17 cells like IL-17A, IL-6 and 
TNF-α [35]. In dextran sodium sulphate (DSS) induced colitis LA administration 
suppressed the production of pro-inflammatory cytokines such as IL-6, TNF-α and 
IL-17 in colon tissues. In vitro LA treatment stimulated Tregs and the production of 
IL-10 [36]. LA treatment downregulated the expression of inflammatory cytokines, 
chemokines and myeloperoxidase in mice model of DSS induced colitis [37]. LA 
treatment also restored the number of colon goblet cells by inducing IL-10 expres-
sion and suppressing proinflammatory cytokines expression in DSS induced colitis 
[38]. LA treatment induced various antiviral cytokines and chemokines such as 
IL-1β, regulated upon activation, normal T cell expressed and presumably secreted 
(RANTES), macrophage colony stimulating factor (MCSF), eotaxin and IFN-α in 
lung and IL-17 in peyer’s patches of influenza virus infected mice [39].
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One of the mechanisms by which LA inhibits the progression of inflamma-
tory diseases is by modulating T cells (Figure 1). It is observed that LA-CGMCC 
7282 along with C. butyricum CGMCC 7281 exerts strong anti-inflammatory 
effects and can prevent Th1 and Th2-type ulcerative colitis [40]. LA protected the 
β-lactoglobulin sensitized mice by reducing the allergic inflammation [41]. LA 
treatment was found to be positively associated with decreased mRNA expression 
of IL-17 and RORγt and reduced proliferation of Th17 cells under both in vitro and 
in vivo models of β-lactoglobulin allergy [41]. In case of HRV infection it is observed 
that varied doses of LA induced different effects. Wen et al. showed that low dose 
of LA enhanced IFN-γ producing T cell response but decreased Tregs response 
the production of TGF-β and IL-10 from Tregs. On the other hand, higher dose 
of LA upregulated Tregs response in gnotobiotic pigs infected with HRV [42]. 
Figure 1. 
Schematic diagram depicting immumodulatory properties and effect of LA on gut permeability and 
dysbiosis. (A) LA influence the activity of various immune cells such as Tregs and Th17 cells, dendritic cells, 
macrophages, natural killer cells, γδ T cells and B cells. (B) LA prevents the increase in gut permeability 
which leads to various diseases such as IBD, IBS, etc. (C) LA restores gut microbiota composition in dysbiotic 
conditions.
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LA strain L-92 attenuated the progression of 2, 4-dinitroflurobenzene induced 
contact dermatitis by regulating Tregs in spleen and cervical lymph nodes. LA-L-92 
administration also enhanced FoxP3, IL-10 and TGF-β levels as compared to the 
controls [43]. LA and B. longum administration to the colitis mice model upregu-
lated the number of Tregs and γδ T cells in intraepithelial lymphocytes [44]. Li et 
al. showed that LA prevents β-immunoglobulin allergy by regulating the balance 
the Tregs/Th17 cells and activation of TLR2/NF-Κb signaling pathways [45]. It is 
observed that LA lysates administration in DSS induced colorectal cancer mice 
model suppressed macrophage (type 2 i.e. M2) polarization, increased the number 
of CD8+ T cells and effector memory T cells and decreased the number of Tregs 
in tumor microenvironment [12]. It is reported that when LA is administered 
after saline challenge in pigs, it increased the number of leucocytes and CD4+ T 
cells whereas when challenged with LPS decreased the number of both CD4+ and 
CD8+ T lymphocytes, leukocytes, expression of IL-6 and TNFα as compared to the 
control diet. LA modulates the activity of other immune cells also. LA enhanced the 
production of IL-10 and IFN-γ from splenocytes induced with concanavalin A (Con 
A) and significantly increased the phagocytic activity of peritoneal macrophages 
[46]. Surface layer protein (Slp) isolated from LA-NCFM reduced the production 
of IL-1β, TNF-α and ROS in LPS induced RAW 264.7 cells via suppression of MAPK 
and NF-κB signaling pathways. Slp also attenuated the production of nitic oxide 
(NO) and prostaglandin E2 (PGE2) by inhibiting the expression of inducible nitric 
oxide synthase (iNOS) and COX-2 [40]. SLP derived from the LA-CICC6074 also 
like LA-NCFM decreased the secretion of TNF-α and enhanced the secretion of NO 
in RAW 264.7 cells [47]. LA stimulated M2 macrophages in peritoneal cavity and 
Tregs and Th2 cells in spleen of DSS treated mice [38]. Administration of LA, L. 
rhamnosus and Bifidobacterium lactis to the mice significantly enhanced the phago-
cytic activity of leukocytes and peritoneal macrophages as compared to the controls 
[48]. It is observed that non-LPS component of LA strain DSS-1 induced the IL-1α 
and TNF-α production by macrophages [49]. Moreover, LA treated macrophages 
showed higher expression of IFN-γ and costimulatory molecule CD40 [33]. LA 
induces activation and maturation of DCs [50]. LA stimulated the IFN-β response 
in DCs in a myeloid differentiation primary response 88 (Myd88) dependent man-
ner [51]. Konstantinov et al., showed that major SlpA of LA-NCFM interacted with 
the DCs via their receptor dendritic cell-specific intercellular adhesion molecule-
3-grabbing non-integrin (DC-SIGN) and modulated the function of DCs and T cells 
[52]. LA-NCFM upregulated the expression of defense genes in DCs such as IL-12 
and IL-10 in a TLR-2 dependent manner [51]. LA administration also decreased the 
degranulation of mast cells and eosinophils [53]. It is observed that pre-treatment 
with LA-L-92 enhanced the natural killer (NK) cells activity in lung [39]. L-92 
also reduced the number of neutrophils in lung of influenza treated mice [39]. It is 
reported that heat killed LA 205 increased the cytolytic activity of NK cells in a time 
and dose dependent manner. LA enhanced the cytotoxicity of NK cells by elevating 
the expression of granulysin which is cytolytic granule component in NK cells [54]. 
In elderly population administration of LA and Bifidobacterium bifidum enhanced 
the frequency of B cells in peripheral blood [55]. LA prevents various diseases by 
modulating the level of antibody production. LA can be beneficial in prevent-
ing food allergy. It is observed that LA-AD031 and Bifidobacterium lactis ADO11 
administration significantly decreased the ovalbumin (OVA) specific IgE, IgA and 
IgG1 in OVA and cholera toxin sensitized mice [53]. Oral administration of heat 
killed LA attenuated hypersensitivity responses in bovine β-lactoglobulin sensitized 
mice model. LA administration decreased inflammatory cells and IgE production. 
Along with IgE production LA treatment enhanced mRNA expression levels of 
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CD25, FoxP3 and TGF-β whereas decreased the expression of IL-17A, RORγt and 
IL-10 in allergic group [56]. Intermediate dose of LA increased rotavirus specific 
IgA and IgG antibody secreting cells and memory B cells in response to rotavirus 
vaccine. Thus, LA administration can be used to improve the efficacy of rotavirus 
vaccine and thus can be effective against rotavirus diarrhea [57]. LA increase the 
IgA, IL-10 and IFNγ producing cells in small intestine [58]. LA improved the immu-
nogenicity of Newcastle Disease vaccines (NDV). Chicks treated with both LA and 
vaccine have increased IgG and NDV antibody titres than the only vaccinated group 
[59]. Feeding of probiotic “dahi” (curd) containing LA and L. casei ameliorated the 
secretory IgA and lymphocyte proliferation in Salmonella enteritidis infected mice 
[60]. These probiotics also increased the proliferative response of splenocytes to 
LPS and con A [48]. Su et al. showed that LA SW1 could function as a promising 
immune adjuvant in DNA vaccine against foot and mouth disease (FMD). Oral 
LA-SW1 enhanced the levels of anti-FMDV antibody titres and FMDV neutral-
izing antibodies [61]. LA lysates also increased the antitumor activity of CTLA-4 
monoclonal antibody [58]. LA not only promotes immune response but also inhibits 
unnecessary lethal immune responses. It is observed that LA along with B. bifidus 
or B. infantis suppressed the mitogen activated cell proliferation of splenocytes and 
PBMCs and arrested the cell cycle at G0/G1 phase. At higher concentrations these 
probiotics inhibited the mitogen activated overactive immune response and at lower 
concentration skewed the balance of Th1/Th2 balance towards Th1 [62].
On the basis of these above discussed studies, we can consider that LA has 
immune regulatory properties. LA has capabilities of regulating various innate 
and adaptive immune cells and therefore can maintain immune homeostasis. 
Altogether, these studies suggest that immunomodulatory properties of LA 
can be employed for regulating the disrupted immune homeostasis in various 
 inflammatory diseases.
2.2 LA role in preventing dysbiosis
Trillions of microbes reside in human gastrointestinal tract. These microbes 
contribute in number of vital functions related to health. These are source of 
essential vitamins and nutrients. Microbes extract energy from food, modulate 
immune system and maintain gut permeability. Gut microbiota usually promotes 
human health but alteration in the gut lead to various clinical manifestations. 
Alteration in gut microbiota is termed as dysbiosis. Gut microbiota can be altered by 
various factors like diet, toxins, pathogens, drugs, antibiotics, etc. [63]. Dysbiosis is 
reported in various diseases like IBS, IBD, diabetes, obesity, cardiovascular diseases, 
asthma, allergy, etc. [63–67]. Dysbiosis is also observed in leukemia where selec-
tive modulation of Lactobacillus species is reported [68]. Dysbiosis is the reason for 
various vaginal diseases like aerobic vaginitis, bacterial vaginosis and vulvovaginal 
candidiasis. In vagina of reproductive aged women microbial homeostasis is main-
tained by the mutualistic relationship between microbes and the host which provide 
protection against vaginal infections by preventing the colonization of opportunis-
tic pathogens [69]. LA, L. iners and L. crispatus are the most abundant bacterial spe-
cies in vaginal tract [70]. Role of LA in preventing dysbiosis is reported by various 
studies. LA-DSS-1 administration improved the abundance of beneficial bacteria 
like Lactobacillus spp. and Akkermansia spp. in caecum [71]. In ulcerative colitis 
patients, supplementation of LA, Lactobacillus salivarius and Bifidobacterium bifidus 
along with anti-inflammatory drug mesalazine prevented intestinal dysbiosis [72]. 
LA also decreased dysbiosis and inflammation induced by Salmonella typhimurium 
infection in Th1 and Th2 biased mice [73]. LA reversed the alterations in the gut 
Acidophiles - Fundamentals and Applications
8
microbiota composition caused due to administration of high fat diet in animals 
[74]. Oral administration of LA along with cobiotic ginger extract encapsulated in 
calcium-alginate beads modulated gut microbiota and prevented 1,2 dimethylhy-
drazine (DMH)/DSS induced colitis and precancerous lesions in rats [75]. Probiotic 
combination consisting of LA, L. helveticus, L. gassari, L. crispatus and L. salivarius 
prevented vaginal dysbiosis by restoring the altered vaginal microbiota to normal 
level. Probiotics combination enhanced the abundance of Lactobacillus while 
decreased the abundance of Enterobacter and Enterococcus [76]. Antibiotics use 
provide protection against wide number of pathogens but also disturb the intestinal 
microflora balance. On the contrary LA is found to be capable of restoring intestinal 
microbial homeostasis. It is observed that LA prevent the dysbiosis induced by 
antibiotic Azithromycin [77]. Synbiotic consisting of inulin, LA, L. plantarum W21, 
L. lactis and Bifidobacterium lactis W51 prevented stress induced dysbiosis and thus 
can be useful in preventing dysbiosis induced in stress related diseases like IBS and 
IBD [78]. LA administration is found effective in treatment of dyspepsia caused 
by dysbiosis [79]. It is observed that the oral intake of LA-GLA-14 and L. rham-
nosus HN001 mixture along with bovine lactoferrin prevent vaginal dysbiosis and 
improve vaginal health. After oral ingestion both the LA-GLA-14 and L. rhamnosus 
HN001 colonize and restore the vaginal microbiota [69]. LA supplementation in 
mice increases short chain fatty acid (SCFA) producing bacteria and thus decreases 
the gram-negative bacteria [80].
2.3 LA role in maintaining gut permeability
Gut barrier is very important for the regulation of the immune homeostasis 
and for preventing the access of pathogens into the gut lumen. Through the leaky 
gut, pathogens invade into the lumen and lead to uncontrolled inflammation. 
Gut barrier is regulated by tight Junctions (TJs) which are present between the 
intestinal epithelial cells. TJs are transmembrane proteins and are divided into four 
groups: claudins, occludin, tricullin and junctional adhesion molecules (JAMs). 
Transmembrane TJs are linked with the actin cytoskeleton through the cytosolic 
scaffold proteins like zona occludens (ZOs) which are of three types ZO-1, ZO-2 
and ZO-3 [81]. Alteration in expression of TJs leads to increase in gut permeability 
and intestinal inflammation which is responsible for various inflammatory diseases 
like IBD [82–86], colon cancer [87] and RA [88].
Several studies have shown that LA administration maintain gut permeability. 
It is observed that the mixture of LA-KLDS1.0901 and L. plantarum KLDS1.0344 
prevents chronic alcohol liver injury in mice by improving the gut permeability. 
Lactobacillus mixture inhibits the increase in gut permeability and reduces the 
abundance of gram-negative bacteria resulting in decrease of LPS entering the 
portal vein thereby suppressing alcohol promoted liver inflammation [80]. LA 
along with L. rhamnosus and B. bifidumi prevented high fat diet induced increase in 
gut permeability and LPS translocation [74]. LA in combination with ginger extract 
restored colonic permeability in DMH-DSS induced colon cancer in Wistar rats [75]. 
Conditioned media of LA significantly prevented the increase in IL-1β induced 
increase in gut permeability. Conditioned media of LA inhibits IL-1β stimulated 
decrease in occludin and increase in claudin-1 expression and thus preserve intes-
tinal permeability by normalizing the expression of occludin and claudin-1 [89]. 
Probiotic combination of LA, L. reuteri, L. casei, Streptococcus thermophiles and 
Bifidobacterium bifidum significantly reduced diabetes incidence and gut perme-
ability [90]. Administration of probiotics LA and Bifidobacterium infantis to the 
pregnant women daily from embryonic day 15- to 2-week-old postnatally main-
tained the intestinal integrity of preweaned offspring. Thus, LA supplementation 
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to pregnant women can promote barrier function of developing offsprings [91]. LA 
and Streptococcus thermophilus enhanced the barrier function of epithelial cells and 
protected the epithelial cells from infection induced by enteroinvasive E. coli by 
limiting its adhesion and invasion [92].
3. Bone remodeling
Bone is a dynamic and metabolically active organ that is being remodeled 
throughout the life of the organisms. Bone remodeling is regulated by three dif-
ferent types of bone cells viz. osteoclasts (bone eating cells), osteoblasts (bone 
forming cells) and osteocytes. Osteoblasts are derived from multipotent stem cells 
that also give rise to fibroblasts, adipocytes, chondrocytes and myoblasts [93]. 
Osteoblasts are responsible for formation of osteoid matrix by depositing col-
lagen which later on get calcified. The major constituent of osteoid matrix is type 
1 collagen which provide resistance against fractures. Osteoid matrix also consists 
of various other non-collagenous proteins which are responsible for various criti-
cal functions of bone [94]. Osteoblast differentiation depends on a number of 
paracrine and transcription factors such as Runx2 and osterix and members of 
bone morphogenetic protein (BMP) family [94]. Osteoclasts are giant polynuclear 
cells that have special ability of resorbing bone [95]. Osteoclasts differentiate from 
monocytic progenitors that also give rise to cells of other monocytic lineages such as 
macrophages, dendritic cells, granulocytes and microglia. Osteoclast differentiation 
depends on two important cytokines: MCSF and receptor activator of nuclear factor 
кb ligand (RANKL). MCSF stimulate proliferation and differentiation of osteoclast 
progenitors. RANKL acts with the help of its receptor RANK and coupling molecule 
TNF receptor associated factor 6 (TRAF 6) to promote the differentiation and 
commitment of precursor cells [95]. Bone resorption starts when osteoclasts attach 
to the surface of bone and form a unique structure called sealing zone. Sealing zone 
permit the osteoclasts to form resorption space. Osteoclasts acidifies the resorp-
tion space to degrade the mineral and organic compartment of the bone. For this 
osteoclast secrete various lysosomal enzymes such as cathepsin K into the resorp-
tion space. To mediate bone resorption osteoclasts, form a specialized structure 
called as ruffled border that increase the surface area for active transport of H+ 
through proton pump. Osteoclasts comparatively resorb a large area of bone and 
then die by apoptosis [94]. Osteocytes are osteoblasts that have been entrapped in 
the osteoid matrix during matrix calcification under the influence of bone specific 
alkaline phosphatase produced by osteoblasts [93, 94]. Osteocytes sense mechanical 
force and tissue strain and send signal to the other osteocytes and osteoblasts by 
forming cellular network termed as canaliculi permeating the entire bone matrix 
[93, 94]. Dynamic equilibrium between the osteoblasts and osteoclasts maintains 
bone integrity. Multiple interactions take place between the bone forming osteo-
blasts and bone resorbing osteoclasts to regulate the process of bone remodeling 
[96]. Osteoblasts positively regulate osteoclast differentiation by secreting RANKL 
and MCSF at pre-osteoblastic stage and negatively by secreting the RANKL decoy 
receptor osteoprotegerin (OPG). Bone remodeling restore microdamages and 
ensure the release of calcium and phosphorus in normal host physiology [97]. 
Bone remodeling consist of four phases viz. activation phase, resorption phase, 
reversal phase and formation phase [97]. In activation phase, MCSF and RANKL 
induce the differentiation of osteoclast progenitors into osteoclasts. During resorp-
tion phase pre-osteoclasts migrate at the surface of bone and get differentiated 
into mature osteoclasts and start resorbing bone. Resorption phase is followed by 
reversal phase where mononuclear cells remove the collagen remnants and prepare 
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the surface for osteoblasts where they can next start the process of bone formation. 
Mononuclear cell also provides various signals for the differentiation and migration 
of osteoblasts [93, 97]. During formation phase osteoblasts replace the resorbed 
bone with new bone [97] (Figure 2). Bone remodeling is regulated by various 
factors such as hormones like estrogen and parathyroid hormone and immune 
cells like T cells and B cells. Below we next discusse the role of immune system in 
regulation of bone health and the potential of LA in preventing bone resorption via 
immunomodulation.
4. Bone and immune system
Bone is an immunomodulatory organ and various immune cells affect the devel-
opment of bone. Bone cells and immune cells interact with each other in the bone 
marrow which is the common niche for the development of both bone and immune 
system. In bone marrow, bone cells and immune cells interact with each other and 
affects each other development. The interaction between the bone and immune sys-
tem is now studied under a new field of immunology termed as Osteoimmunology, 
a term coined by Choi et al. in 2006. Impact of various immune cells and cytokines 
secreted by immune cells on bone development is now known [97]. It is observed 
Figure 2. 
Schematic representation of bone remodeling. Bone remodeling occurs in four phases viz. 1) Activation phase: 
MCSF and RANKL induce the differentiation of osteoclast progenitors into osteoclasts. 2) Resorption phase: 
Mature osteoclast with unique ruffled border starts resorption of bone by secreting cathepsin K, and H+ in 
sealing zone. After resorption osteoclasts detach from the surface of bone and undergo apoptosis. 3) Reversal 
phase: During reversal phase osteoblasts precursor get differentiated into mature osteoblasts and are recruited 
to the resorption site. 4) Formation phase: Osteoblasts get occupied in the resorbed lacuna and start depositing 
the bone matrix. After formation phase osteoid gets mineralized and bone surface returns to resting phase with 
bone lining cells.
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that cytokines such as IL-1, TNF-α, IL-6, IL-11, IL-15 and IL-17 induce bone resorp-
tion whereas cytokines such as IL-4, IL-10, IL13, IL-18, IFN-γ and granulocyte 
macrophage colony stimulating factor (GM-CSF) prevent bone loss. In various bone 
disorders the role of immune system has been discovered such as osteoporosis, RA 
and periodontitis. Osteoporosis is an inflammatory disease and several immune 
cells affect the development of osteoporosis. To study the immunology of osteopo-
rosis we integrative biology started a novel field termed by us as “Immunoporosis” 
which deals specifically with the role of immune cells in osteoporosis [96]. Th17 
cells and Tregs have most vital role in the development of bones and their balance 
is required for proper regulation of bone mass. CD4+FOXP3+ Tregs enhance bone 
mass by inhibiting osteoclastogenesis by directly suppressing the production of 
RANKL and MCSF [98]. Another mechanism by which CD4+FOXP3+ Tregs inhibit 
osteoclastogenesis or bone loss is by interacting with the CD80 and CD86 present 
on osteoclast precursors via CTLA-4, thereby inhibiting osteoclast differentiation 
[96]. Not only CD4+FOXP3+ Tregs, now the effect of CD8+FOXP3+ Tregs on bone 
is also discovered. It is observed that the CD8+ Tregs prevent bone loss by inhibit-
ing the formation of actin ring resulting in suppression of osteoclastogenesis [99]. 
Unlike Tregs, Th17 cells promote bone loss by inducing osteoclastogenesis via 
secretion of RANKL. Th17 also secrete IL-17 which induce bone loss by promot-
ing RANKL expression on osteoclastogenesis supporting cells and by stimulating 
expression of inflammatory cytokines such as TNFα, IL-1 and IL-6 which further 
upregulate RANKL expression [9, 100]. Imbalance of Tregs and Th17 cells leads 
to bone loss which occurs during post-menopausal osteoporosis (PMO). Lack of 
estrogen promotes PMO. Estrogen prevents osteoporosis by inhibiting osteoclasto-
genesis but estrogen deficiency causes increased osteoclastogenesis by stimulating 
differentiation of Th17 cells. We also found in our studies that level of Th17 cells and 
inflammatory cytokines such as TNFα, IL-6, IL-17 and RANKL increased during 
post-menopausal osteoporosis [9, 101, 102]. Several studies have shown the role of 
Tregs and Th17 cells imbalanc in pathogenesis of RA [103]. The frequency of Th17 
cells are enhanced in the joints and synovial fluid of RA patients [104] whereas the 
percentage of Tregs get significantly decreased in RA patients [105]. Similarly, the 
role of Tregs and Th17 cells imbalance is also found to be associated with periodon-
titis inflammation [106] and osteoarthritis [107]. Apart from these various other 
immune cells such as Th1, Th2, Th9 cells and γδ T cells are also involved in regulat-
ing bone health [97].
4.1 Role of LA in regulation of osteoimmune system
As immune system has such an important role in regulation of bone health, 
proper maintenance of immune homeostasis is very much required. Immune homeo-
stasis for bone regulation is maintained by various factors such as estrogen hormone. 
Various strategies are used to prevent bone loss due to immune disruptions such as 
Denosumab, rituximab and TNF blockers [108, 109]. These strategies are proven 
effective but they also exert various adverse effects in the long run. Recently the use 
of probiotics is found to be effective in treatment of various inflammatory disorders 
such as IBD, obesity, diabetes, etc. [110–112]. Probiotics are also considered for the 
treatment of various bone disorders. LA is one of these probiotics. It is observed 
that LA has great potential of treating various bone pathologies. From comparison 
of different Lactobacillus species, it is observed that the effect of Lactobacillus on 
bone health is species dependent and LA has showed the most significant effect on 
bone parameters such as bone mineral density (BMD) and bone mineral content 
(BMC) among other Lactobacillus species [113]. In rat model of apical periodontitis, 
it is observed that level of alkaline phosphatase is significantly higher whereas the 
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level of TRAP and RANKL is significantly lower in LA consumed groups [114]. It is 
reported that LA has antiarthritic properties and prevented Fruend’s complete adju-
vant mediated arthritis in female wistar rats [115]. It is observed that LA supernatant 
increased the proliferation of bone marrow stromal cells derived from rats [116]. It is 
observed in study from our group that LA can prevent bone loss by modulating the 
host immune system. We reported that LA improved both cortical and trabecular 
bone microarchitecture as well as enhanced the BMD and heterogeneity of bone in 
ovariectomized mice by skewing the Treg-Th17 cell balance (Figure 3). LA admin-
istration promoted the development of anti-osteoclastogenic Tregs and inhibited 
the osteoclastogenic Th17 cells in ovariectomized mice. LA supplementation also 
Figure 3. 
Role of Tregs/Th17 cells axis in regulation of bone health: (A) Tregs inhibit the differentiation of osteoclasts 
by secreting IL-10. Tregs also suppress osteoclastogenesis or bone loss by interacting with the CD80 and CD86 
present on osteoclast precursors through cytotoxic T lymphocyte associated antigen 4 (CTLA-4). Th17 promote 
osteoclastogenesis via secretion of RANKL and IL-17. IL-17 induce expression of RANKL on osteoclastogenesis 
promoting cells. (B) In normal healthy conditions there is balance between Tregs and Th17 cells but during 
osteoporosis or other bone diseases like RA and periodontitis number of Th17 cells is increased which further 
leads to bone loss. LA treatment in these diseases restores the balance of Tregs and Th17 cells and thus prevent 
bone resorption.
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Source Effect on bone Reference
1. ATCC 4356 ATCC Modulated Treg-Th17 cell axis 
and inhibited the expression of 
inflammatory cytokines
[9]
2. ATCC 314 ATCC Prevented freund’s complete 
adjuvant induced arthritis by 
decreasing the oxidative stress
[115, 118]
2. ATCC 11975 ATCC NR —
3. ATCC 4375D-5 ATCC NR —
4. ATCC 53671 ATCC NR —
5. ATCC 4355 ATCC NR —
6. ATCC 4357 ATCC NR —
7. ATCC 9224 ATCC NR —
8. ATCC BAA-2832 ATCC NR —
9. ATCC 13651 ATCC NR —
10. ATCC 11975 ATCC NR —
11. ATCC 832 ATCC NR —
12. ATCC 43121 ATCC NR —
13. ATCC 53544 ATCC NR —
14. ATCC 53545 ATCC NR —
15. ATCC 53546 ATCC NR —
16. ATCC 4796 ATCC NR —
18. ATCC 53671 ATCC NR —
19. ATCC 700396 ATCC NR —
20. LA-1 Chr. Hansen, Demark Decreased the levels of 
inflammatory cytokines and 
enhanced the levels of anti-
inflammatory cytokines in joints 
of osteoarthritic rats
[117]
21. LA-2 Chr. Hansen, Demark NR —
22 LA-3 Chr. Hansen, Demark NR —
23 LA-4 Chr. Hansen, Demark NR —
24 LA-5 Chr. Hansen, Demark NR —
25 LA-14 Chr. Hansen, Demark Decreased the inflammatory 
cytokines IL-1β and IL-6 in 
experimental apical periodontitis
[119]
26 DDS-1 Nebraska cultures, 
Nebraska
NR —
27 NCFM Dansico, Madison NR —
28 SBT-2026 Snow brand milk 
products, Japan
NR —
ATCC: American Tissue Culture Collection.
NR: Not reported.
Table 1. 
Different strains of LA and their effects on bone.
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attenuated the expression of osteoclastogenic cytokines such as IL-6, IL-17, RANKL, 
TNF-α and increased the expression of anti-osteoclastogenic cytokines like IL-10 
and IFN-γ. Thus, LA has therapeutic effects and it can be used as an osteoprotec-
tive agent [9]. LA prevented monosodium iodoacetate induced osteoarthritis and 
reduced cartilage destruction via inhibition of proinflammatory cytokines produc-
tion [117]. LA supplementation along with L. rhamnosus significantly decreased the 
inflammatory cytokines IL-1β and IL-6 and enhanced the expression of IL-10 as 
compared to the controls in experimental apical periodontitis [114]. LA supplemen-
tation upregulated anti-inflammatory cytokines and downregulated inflammatory 
cytokines in serum in experimental arthritis model [118]. Thus, LA has great ability 
of preventing inflammatory bone loss and of regulating osteoimmune system 
(Table 1).
5. Bone and dysbiosis
A number of microbes are localized in the gut. Some of them are beneficial for 
health whereas others are pathogenic and a balance of these microbes is required 
for normal physiological functioning of body. But due to several reasons like 
surgery, medications, irradiation and antibiotics this balance is dysregulated which 
leads to modifications in gut microbiota composition [3]. Dysbiosis is observed in 
various bone pathologies. Normally gut is dominated by four types of microbial 
phyla: Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria. Firmicutes and 
Bacteroidetes constitutes over 90% of the total gut microbiota and dysregulation of 
Firmicutes/Bacteroidetes ratio affect various biological processes like bone remodel-
ing. During osteoporosis Firmicutes counts significantly increases whereas counts 
of Bacteroidetes significantly decreases [120–122]. In osteoporosis increase in the 
number of Faecalibacterium and Dialister genera is also reported [123]. Dysbiosis 
is also observed in RA and periodontitis [124, 125]. Although, LA mainly prevents 
bone loss by regulating immune homeostasis it also restores the gut microbiota 
composition in various diseases as discussed above. Thus, it can be possible that LA 
can also inhibit bone resorption by preventing dysbiosis.
6. Bone health and gut permeability
Gut permeability has very important role in regulation of bone health. Various 
studies have shown that increase in gut permeability is associated with bone loss. 
Collins et al. group measured the intestinal permeability after 1, 4 and 8 weeks 
of ovx surgery and they found increased intestinal permeability one week after 
ovariectomy along with the increase in inflammatory cytokines like IL-1β and 
TNFα which are responsible for bone loss [126]. Estrogen deficiency during post-
menopausal osteoporosis is responsible for increase in gut permeability. Estrogen 
has very significant role in regulating the gut barrier. It maintains gut barrier 
through its receptors which are present on the intestinal epithelial cells. There are 
two types of estrogen receptors: ERα and ERβ. ERβ has very important role in the 
regulation of TJs as ERβ−/− mice has disrupted expression of tight junction proteins 
[39]. Various other studies proved the role of estrogen in regulation of gut barrier. 
Langen et al. reported decreased expression of ERβ and increased gut permeability 
in IBD patients [127]. Gut permeability decreases during oestrous phase whereas 
it is increased during dioestrus phase of rats and this increase in intestinal perme-
ability during dioestrus phase can be prevented by treatment with oestradiol which 
upregulate the expression of occludin [128]. Estrogen and progesterone treatment 
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decreases gut permeability and thus prevent secretion of inflammatory cytokines in 
IBD models [129]. LA prevents leaky gut in various diseases as discussed above and 
thus it can be possible that LA is effective in preventing leaky gut induced bone loss 
also. In summary we can say that by maintaining immune homeostasis and regulat-
ing both gut permeability and dysbiosis LA prevents bone resorption (Figure 4).
7. Conclusion
In the last few years, several studies have delineated the role of LA in preventing 
a number of inflammatory and metabolic disorders. LA prevents these disorders 
through various mechanism such as by modulating the host immune system, by 
maintaining the gut permeability along with preventing dysbiosis. The role of LA 
in suppressing bone loss also highlights the importance of LA in regulating bone 
health. LA enhances bone mass and prevents several bone diseases like osteopo-
rosis, arthritis and periodontitis via regulating the immune homeostasis. Thus, 
immunomodulatory property of LA is of utmost importance in management of 
various bone pathologies. LA can also prevent bone resorption by regulating the 
leaky gut and dysbiosis. Thus, LA has immense potential as a probiotic and can be 
used as a medical therapy for treatment of bone loss in humans but before that a lot 
of research is further needed to be done on the efficacy along with the associated 
pros and cons of LA on human health.
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